Form 4: NEO CFO Sells Shares for Tax Obligations
Insider Transaction Report
NeoGenomics CFO Jeffrey Scott Sherman disposed of 11,938 common shares to cover tax liabilities from restricted stock vesting.
Summary
- Jeffrey Scott Sherman, Chief Financial Officer of NeoGenomics Inc. (NEO), reported a disposition of 11,938 shares of common stock.
- The transaction occurred on December 7, 2025, and was a surrender of shares to NeoGenomics, Inc. for retirement to satisfy tax obligations related to the December 1, 2025 vesting of restricted stock.
- The shares were disposed of at a price of $0, indicating a non-sale transaction for tax purposes.
- Following this transaction, Mr. Sherman directly beneficially owns 176,394 shares of common stock.
- Mr. Sherman also holds various derivative securities, including stock options and restricted/performance stock units, with different vesting schedules and exercise prices.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary transaction for tax purposes related to executive compensation. It is neutral in terms of company performance or strategic direction.
Positives
- The transaction is a routine, non-discretionary event related to tax withholding upon the vesting of restricted stock, indicating the executive is receiving equity compensation.
Negatives
- The disposition of shares, while for tax purposes, reduces the direct common stock holdings of the CFO.
Future Outlook
The filing details future vesting schedules for various equity awards, indicating ongoing long-term incentive compensation for the Chief Financial Officer. Performance stock units are tied to future share growth goals and, for some grants, revenue growth goals, suggesting management's incentives are aligned with company performance.
Industry Context
This Form 4 filing is a standard disclosure of an insider transaction related to equity compensation. It reflects common practices in executive compensation within publicly traded companies, where restricted stock units vest over time and a portion is often withheld to cover tax liabilities. It does not provide specific industry-wide insights beyond typical executive compensation structures.
Comparison to Industry Standards
- The use of restricted stock units (RSUs), performance stock units (PSUs), and stock options as part of executive compensation is a common practice across various industries, including the biotechnology and diagnostics sector where NeoGenomics operates.
- The disposition of shares to cover tax obligations upon vesting is a standard, non-discretionary event for executives, consistent with compensation practices at comparable companies.
Related Party Transactions
- The disposition of 11,938 shares to NeoGenomics, Inc. for retirement to satisfy tax obligations related to restricted stock vesting is a transaction between the company and an insider.
Stakeholder Impact
- Shareholders: The disposition of shares for tax purposes is a routine event and does not typically have a significant direct impact on existing shareholders beyond the minor dilution from the original grant of equity awards.
- Employees (CFO): The CFO continues to hold substantial equity in the company through common stock, stock options, and various types of restricted and performance units, aligning his interests with long-term company performance.
Next Steps
- Continued vesting of various stock options, restricted stock units, and performance stock units for the CFO on their respective schedules.
- Achievement of share growth and revenue growth goals for performance stock units to vest.
Key Dates
| Date | Description |
|---|---|
| 2022-12-05 | Grant date for 249,169 stock options with an exercise price of $11.62. |
| 2023-05-11 | Grant date for 73,016 stock options with an exercise price of $19.65, 39,016 restricted stock units, and 39,016 performance stock units. |
| 2023-12-07 | First tranche vesting date for 249,169 stock options granted on December 5, 2022. |
| 2024-02-23 | Grant date for 77,913 stock options with an exercise price of $16.45, 46,606 performance stock units, and 46,606 restricted stock units. |
| 2025-02-20 | Closing price used to calculate the premium exercise price for stock options granted on February 21, 2025. |
| 2025-02-21 | Grant date for 214,900 stock options with an exercise price of $13.05 and 126,476 restricted stock units. |
| 2025-12-01 | Vesting date of restricted stock, which triggered the tax obligations. |
| 2025-12-07 | Transaction date for the disposition of 11,938 common shares to satisfy tax obligations. |
| 2025-12-09 | Signature date of the reporting person's attorney-in-fact for the Form 4 filing. |
| 2026-04-13 | Vesting date for 59,382 restricted stock units. |
| 2026-05-11 | Expiration date for 39,016 performance stock units granted on May 11, 2023. |
| 2027-02-23 | Expiration date for 46,606 performance stock units granted on February 23, 2024. |
| 2029-12-05 | Expiration date for 249,169 stock options granted on December 5, 2022. |
| 2030-05-11 | Expiration date for 73,016 stock options granted on May 11, 2023. |
| 2034-02-23 | Expiration date for 77,913 stock options granted on February 23, 2024. |
| 2035-02-21 | Expiration date for 214,900 stock options granted on February 21, 2025. |
Keywords
NeoGenomics, NEO, Form 4, Insider Transaction, CFO, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.